Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY2A | P04746 | 8/20 | 0.63 |
| ▸ | MGAM | O43451 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | SI | P14410 | 4/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TREH | O43280 | 1/20 | 0.50 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Validamycin A SCHEMBL8819801 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin SCHEMBL3121491 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL19231832 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL14408710 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL10033386 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL14409005 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL15906030 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL14408718 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL16028080 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A | |
| Validamycin A SCHEMBL29451180 | 0.94 | AMY2A (0.56) | AMY2AMGAMGAASIAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111995646-B | Separation and purification method of validamycin | 浙江工业大学 | 2022-03-18 | — | — | CN | claimed |
| CN-111995646-B | Separation and purification method of validamycin | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-111995646-B | Separation and purification method of validamycin | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| US-7271158-B2 | Treatment of rumen acidosis with α-amylase inhibitors | PFIZER INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271158-B2 | Treatment of rumen acidosis with α-amylase inhibitors | PFIZER INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1745790-A2 | Treatment of rumen acidosis with alpha-amylase inhibitors | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-20050233983-A1 | Treatment of rumen acidosis with alpha-amylase inhibitors | BANKS BERNARD J | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233983-A1 | Treatment of rumen acidosis with alpha-amylase inhibitors | SI, GANAB, AMY1A | AMY2A 13/4885MGAM 7/4885GAA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.